Skip to content

Effect of Kangfuxin on wound healing and pain control of postoperative pharyngeal ulcer

Effect of Kangfuxin on wound healing and pain control of postoperative pharyngeal ulcer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040423
Enrollment
Unknown
Registered
2020-11-28
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign pharyngeal mass, tonsillitis

Interventions

Experimental group:Give Kangfuxin Liquid to take
Control group:Normal solution

Sponsors

West China Hospital, West China Medical School, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with chronic tonsillitis, tonsillar hypertrophy, adenoid hypertrophy, and benign mass of pharynx were treated with bilateral tonsillectomy, adenoidectomy and pharyngeal benign tumor; 2. Children and adolescents aged 2-16 years were divided into children group and adults group, and the guardians of children group and patients of adult group voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. craniofacial abnormalities, including cleft lip and palate or submucosal cleft palate, or any anatomical or general condition that interferes with general anesthesia or the removal of tonsils and adenoids in a standard manner; 2. serious health problems, including severe cardiopulmonary diseases (e.g., cystic fibrosis, congenital heart disease); sickle cell disease; poorly controlled asthma 1 time); epilepsy needs drug treatment; diabetes mellitus (type 1 or 2) needs drug treatment; diagnosed heart disease or pulmonary heart disease; stage II hypertension (HTN) with a history of more than 99% and / or drug treatment; mental retardation; chronic special infection (such as HIV); 3. patients with confirmed malignant tumor; 4. patients or family members request withdrawal from the study or compliance; 5. mental or behavioral disorders that require or may require the initiation of new drugs, treatments or other special treatments within 14 days after surgery; 6. confirmed genetic, craniofacial, neurological or psychiatric disorders; 7. current use of ADHD drugs, psychotropic drugs, hypnotics, hypoglycemic agents or insulin, antihypertensive drugs, growth hormone, anticonvulsant, anticoagulants, daily Oral corticosteroids; (9) participants who were considered unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Pain feeling;

Countries

China

Contacts

Public ContactLei Lei

West China Hospital, West China Medical School, Sichuan University

775293076@qq.com+86 18200576610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026